# MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

#### **GENERAL INFORMATION**

<u>Requestor Name</u> <u>Respondent Name</u>

Sentrix Pharmacy and Discount, L.L.C. Old Republic Insurance Company

MFDR Tracking Number Carrier's Austin Representative

M4-17-2850-01 Box Number 44

**MFDR Date Received** 

May 26, 2017

### **REQUESTOR'S POSITION SUMMARY**

Requestor's Position Summary: "The insurance carrier, Broadspire failed to take final action on the claim within the 45-day period set forth in TAC §133.240. Specifically the claim was submitted on 3/12/17 and it was received by the provider on 3/6/17 [sic] ... and no action was taken on the claim. The Pharmacy had submitted a second request for payment (on 4/28/17) ... and it was received by the provider on 5/15/17 ... Again, no action was taken on the claim."

Amount in Dispute: \$2,078.06

#### **RESPONDENT'S POSITION SUMMARY**

Respondent's Position Summary: "The bill has been disputed as the medications were not preauthorized."

Response Submitted by: Broadspire

## SUMMARY OF FINDINGS

| Dates of Service | Disputed Services                  | Amount In<br>Dispute | Amount Due |
|------------------|------------------------------------|----------------------|------------|
| March 6, 2017    | Pharmacy Services – Compound Cream | \$2,078.06           | \$1,718.06 |

#### FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

## **Background**

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.502 sets out the procedures for pharmaceutical benefits.
- 3. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 4. 28 Texas Administrative Code §134.530 sets out the closed formulary requirements for claims not subject to certified networks.

- 5. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:
  - 39 Denied Medication Not Authorized.

### <u>Issues</u>

- 1. Is Old Republic Insurance Company's denial of payment supported?
- 2. Is Sentrix Pharmacy and Discount, L.L.C. (Sentrix) eligible for reimbursement of the service in question?

#### **Findings**

- 1. Old Republic Insurance Company (Old Republic) denied the disputed service stating, "Denied Medication Not Authorized." 28 Texas Administrative Code §134.530(b)(2) states that preauthorization is **only** required for:
  - drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp
    (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;
  - any compound that contains a drug identified with a status of "N" in the current edition of the ODG
     Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and
     any updates; and
  - any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

The division finds that the compound in question does not include a drug identified with a status of "N" in the current edition of the ODG, *Appendix A*. Old Republic failed to articulate any arguments to support its denial for preauthorization. Therefore, the division concludes that the compound in question did not require preauthorization and Old Republic's denial for this reason is not supported.

- 2. Sentrix is seeking reimbursement of \$2,078.06 for a compound cream dispensed on March 6, 2017, containing the following ingredients:
  - Salt Stable LS Base, NDC 00395602157, \$572.54
  - Baclofen 4%, NDC 00395803243, \$342.05
  - Amitriptyline 2%, NDC 00395804843, \$87.55
  - Ketoprofen 10%, NDC 00395805643, \$250.80
  - Amantadine 8%, NDC 00395805843, \$465.12
  - Gabapentin 5%, NDC 10695003507, \$360.00

28 Texas Administrative Code §134.503 applies to the services in dispute and states, in pertinent part:

- (c) The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:
  - (1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:
    - (A) Generic drugs: ((AWP per unit) x (number of units) x 1.25) + \$4.00 dispensing fee per prescription = reimbursement amount;
    - (B) Brand name drugs: ((AWP per unit) x (number of units)  $\times 1.09$ ) + \$4.00 dispensing fee per prescription = reimbursement amount;
    - (C) When compounding, a single compounding fee of \$15 per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection; or
  - (2) notwithstanding §133.20(e)(1) of this title (relating to Medical Bill Submission by Health Care Provider), the amount billed to the insurance carrier by the:
    - (A) health care provider; or
    - (B) pharmacy processing agent only if the health care provider has not previously billed the insurance carrier for the prescription drug and the pharmacy processing agent is billing on behalf of the health care provider.

The compound in dispute was billed by listing each drug included in the compound and calculating the charge for each drug separately as required by 28 Texas Administrative Code §134.502(d)(2). Reimbursement is calculated as follows:

| Ingredient       | NDC &       | Price/        | Total | AWP Formula       | Billed Amt | Lesser of  |
|------------------|-------------|---------------|-------|-------------------|------------|------------|
|                  | Туре        | Unit          | Units | §134.503(c)(1)    | §134.503   | (c)(1) and |
|                  |             |               |       |                   | (c)(2)     | (c)(2)     |
| Salt Stable LS   | 00395602157 | \$3.36        | 170.4 | \$3.36 x 170.4 x  | \$572.54   | \$572.54   |
| Base             | Brand Name  | \$3.30        | gm    | 1.09 = \$624.07   |            |            |
| Baclofen 4%      | 00395803243 | \$35.63       | 9.6   | \$35.63 x 9.6 x   | \$342.05   | \$342.05   |
|                  | Generic     | Ş33.03        | gm    | 1.25 = \$427.56   |            |            |
| Amitriptyline 2% | 00395804843 | \$18.24       | 4.8   | \$18.24 x 4.8 x   | \$87.55    | \$87.55    |
|                  | Generic     | <b>310.24</b> | gm    | 1.25 = \$109.44   |            |            |
| Ketoprofen 10%   | 00395805643 | \$10.45       | 24.0  | \$10.45 x 24 x    | \$250.80   | \$250.80   |
|                  | Generic     | \$10.45       | gm    | 1.25 = \$313.50   |            |            |
| Amantadine 8%    | 00395805843 | \$24.225      | 19.2  | \$24.225 x 19.2 x | \$465.12   | \$465.12   |
|                  | Generic     | \$24.225      | gm    | 1.25 = \$581.40   |            |            |
| Gabapentin 5%    | 10695003507 | NA            | 12.0  | NA                | \$360.00   | \$0.00     |
|                  | Invalid NDC | IVA           | gm    | INA               |            |            |
|                  |             |               |       | _                 | Total      | \$1,718.06 |

The total allowable reimbursement for the compound in dispute is \$1,718.06. This amount is recommended.

#### **Conclusion**

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$1,718.06.

#### ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$1,718.06, plus applicable accrued interest per 28 Texas Administrative Code §134.130, due within 30 days of receipt of this order.

### **Authorized Signature**

|           | Laurie Garnes                          | July 21, 2017 |  |
|-----------|--|---------------|--|
| Signature | Medical Fee Dispute Resolution Officer | Date          |  |

# YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, *37 Texas Register 3833*, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings* **and** *Decision* together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.